Dennis Burns

Services Offered: Corporate strategy, outsourced business development, pharmaceutical brand management services.

Pharmaceutical, Biotechnology, and Medical Device Experience: Dennis Burns has twenty-five years of successful market development experience at Fortune 500 pharmaceutical and consumer companies as well as medical device firms and biotech start-ups. He led the Internal Adhesives Division of CLOSURE Medical (NASDAQ: CLSR, maker of DERMABOND®) as Vice President/ General Manager identifying new surgical adhesives. Previously, Mr. Burns was President of EpiGenesis Pharmaceuticals, a start-up developing asthma drugs and was Development Advisor to Westaim Biomedical in Edmonton, Canada on ACTICOAT® antimicrobial dressings. He has consulted for diagnostics firms, specialty chemical and biomaterials companies. Also, Mr. Burns was President/ CEO of Macronex, a venture-backed immunotherapy biotech company in Research Triangle Park, NC where he completed financing rounds and several strategic collaborations.

While at Johnson & Johnson for 15 years, Mr. Burns was a founding Board Member and Vice President, Licensing and International Development at Ortho Biotech, concluding deals with biopharma firms and universities along with supporting the European expansion of EPREX®/PROCRIT® erythropoietin, now a $4 billion business. Earlier, he directed start-up units including:

• JJSBP, which developed nuclear imaging agents to target cancer and cardio-vascular disease and concluded the first strategic alliance between J&J and Centocor, then an independent biotech company;
   
• Ortho Immunobiology Division that developed J&J's first therapeutic biotechnology product (OKT 3 MoAb for transplant therapy) where he oversaw the biological production scale-up, staffing of the new operation (became Ortho Biotech) and overseas development plans;
   
• The J&J Consumer team that created ACT® dental rinse, still a major retail brand.

Earlier in his career, Mr. Burns held posts in Marketing, Sales and Regulatory Affairs for Richardson-Vicks, an OTC drug/toiletries firm that is now part of Proctor & Gamble.

A founding Director of the North Carolina Biosciences Industry Organization (NC BIO), and active in the Licensing Executives Society International (LES), Mr. Burns has spoken at industry meetings on Strategic Alliances, International Development, Entrepreneurial Management and Technology Transfer. He was educated at Manhattan College (BS, Biology) and the Yale University School of Medicine and has taken Executive courses at New York University and Duke's Fuqua School of Business.

Mr. Burns is a principal of TCG (www.t-c-group.com).

The BioPharm Team
c/o PharmSupport
P.O. Box 13724, Research Triangle Park, NC 27709
(919) 403-7704 (phone)
inquiries@biopharmteam.com (e-mail)